UPDATE: Bloom Burton & Co Downgrades Oncolytics Biotech to Hold on Valuation

Bloom Burton & Co. reduced its rating on Oncolytics Biotech (NASDAQ: ONCY ) from Buy to Hold. Bloom Burton & Co commented, "We maintain our cautious outlook on the outcome of the ongoing head & neck cancer trial but are encouraged with these early data. If the trial shows